Edition:
India

Correvio Pharma Corp (CORV.OQ)

CORV.OQ on NASDAQ Stock Exchange Capital Market

2.62USD
16 Sep 2019
Change (% chg)

-- (--)
Prev Close
$2.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
16,992
52-wk High
$4.60
52-wk Low
$1.43

Latest Key Developments (Source: Significant Developments)

Correvio Highlights FDA Acceptance Of United Therapeutics' Trevyent New Drug Application
Thursday, 12 Sep 2019 

Sept 12 (Reuters) - Correvio Pharma Corp ::CORREVIO HIGHLIGHTS FDA ACCEPTANCE OF UNITED THERAPEUTICS' TREVYENT NEW DRUG APPLICATION.CORREVIO PHARMA CORP - EXPECTS TO FILE REGULATORY SUBMISSIONS FOR TREVYENT IN EUROPE IN MID-2020.  Full Article

Correvio Announces Pricing Of Public Offering Of Common Shares
Friday, 2 Aug 2019 

Aug 2 (Reuters) - Correvio Pharma Corp ::CORREVIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES.SAYS OFFERING OF 8.00 MILLION COMMON SHARES PRICED AT $1.50PER SHARE.  Full Article

Correvio Announces At The Market Offering
Thursday, 14 Mar 2019 

March 14 (Reuters) - Correvio Pharma Corp ::CORREVIO ANNOUNCES AT THE MARKET OFFERING.CORREVIO PHARMA CORP - ENTERED INTO AT MARKET SALES ISSUANCE AGREEMENT DATED MARCH 13, 2019 WITH CANTOR FITZGERALD & CO..CORREVIO PHARMA CORP - UNDER AGREEMENT, CO MAY SELL COMMON SHARES OF UP TO $50 MILLION, SUBJECT TO LIMIT OF $12 MILLION UNDER ATM PROSPECTUS SUPPLEMENT.CORREVIO PHARMA - PLANS TO USE NET PROCEEDS FOR PREPARATIONS FOR FUTURE PRODUCT LAUNCHES, INCLUDING EXPECTED RESUBMISSION OF AN NDA FOR BRINAVESS.  Full Article

Correvio Pharma Reports Q4 Loss Per Share Of $0.18
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Correvio Pharma Corp ::CORREVIO REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.COMPANY ON TRACK TO RESUBMIT BRINAVESS NDA IN Q2 2019.Q4 LOSS PER SHARE $0.18.Q4 REVENUE $8.9 MILLION VERSUS $7.0 MILLION.CORREVIO PHARMA - MARK H.N. CORRIGAN HAS BEEN NAMED CORREVIO'S NEXT CHIEF EXECUTIVE OFFICER, EFFECTIVE MARCH 14, 2019.CORREVIO PHARMA - JUSTIN RENZ, CHIEF FINANCIAL OFFICER OF CORREVIO, ASSUMED THE RESPONSIBILITIES OF PRESIDENT.  Full Article

Correvio Announces Amendment To Term Loan With Crg-Managed Funds
Monday, 11 Mar 2019 

March 11 (Reuters) - Correvio Pharma Corp ::CORREVIO ANNOUNCES AMENDMENT TO TERM LOAN WITH CRG-MANAGED FUNDS.CORREVIO PHARMA CORP - AMENDMENT PROVIDES FOR UP TO AN ADDITIONAL $10 MILLION IN DEBT FUNDING.CORREVIO PHARMA CORP - REMAIN ON TRACK TO RESUBMIT BRINAVESS NDA DURING Q2 OF 2019.  Full Article

Correvio Pharma Corp - Chief Financial Officer, Justin Renz, Appointed President
Wednesday, 2 Jan 2019 

Correvio Pharma Corp ::CORREVIO ANNOUNCES CHIEF EXECUTIVE OFFICER SUCCESSION PLAN AND OTHER BOARD AND EXECUTIVE CHANGES.CORREVIO PHARMA CORP - CHIEF FINANCIAL OFFICER, JUSTIN RENZ, APPOINTED PRESIDENT.CORREVIO PHARMA CORP - VANDA DE CIAN, MD, TO JOIN BOARD OF DIRECTORS.CORREVIO PHARMA CORP - HUNTER TO REMAIN A MEMBER OF BOARD OF DIRECTORS.CORREVIO PHARMA CORP - MARK H.N. CORRIGAN, MD TO SUCCEED WILLIAM HUNTER, MD AS CHIEF EXECUTIVE OFFICER BY END OF Q1 2019.CORREVIO PHARMA CORP - DE CIAN WILL SERVE AS A MEMBER OF NOMINATING, GOVERNANCE AND COMPENSATION COMMITTEES.CORREVIO PHARMA CORP - HUNTER WILL TRANSITION OUT OF HIS CURRENT ROLE BY END OF Q1 OF 2019.  Full Article

Correvio Announces Brinavess Eligibility For Patent Extension
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Correvio Pharma Corp ::CORREVIO ANNOUNCES BRINAVESS ELIGIBILITY FOR PATENT EXTENSION.CORREVIO PHARMA - RECEIVED INDEPENDENT REGULATORY AND LEGAL OPINIONS THAT BRINAVESS MAY QUALIFY FOR UP TO 5-YEAR PATENT EXTENSION FROM USPTO.CORREVIO PHARMA CORP - WILL BE RESUBMITTING A NEW DRUG APPLICATION (NDA) FOR BRINAVESS TO FDA DURING Q2 OF 2019.  Full Article

Correvio Announces Intention To Re-File Brinavess NDA In Q2 2019
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - Correvio Pharma Corp ::CORREVIO ANNOUNCES INTENTION TO RE-FILE BRINAVESS NDA IN SECOND QUARTER 2019.CORREVIO PHARMA CORP - PLANS TO RESUBMIT BRINAVESS (VERNAKALANT HYDROCHLORIDE, IV) NEW DRUG APPLICATION (NDA) DURING Q2 OF 2019.CORREVIO PHARMA CORP - NO ADDITIONAL STUDIES REQUIRED FOR RESUBMISSION.  Full Article

Correvio Q1 Loss Per Share $0.24
Wednesday, 16 May 2018 

May 15 (Reuters) - Cardiome Pharma Corp ::CORREVIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE $6.5 MILLION VERSUS I/B/E/S VIEW $5.9 MILLION.Q1 LOSS PER SHARE $0.24.Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.CORREVIO PHARMA CORP - AT MARCH 31, 2018, COMPANY HAD CASH AND CASH EQUIVALENTS OF $13.6 MILLION.  Full Article

Cardiome Announces Amendment To Term Loan Agreement With CRG Managed Funds
Saturday, 7 Apr 2018 

April 6 (Reuters) - Cardiome Pharma Corp ::CARDIOME ANNOUNCES AMENDMENT TO TERM LOAN AGREEMENT WITH CRG-MANAGED FUNDS.ENTERED INTO FIRST AMENDING AGREEMENT TO ITS MAY 11, 2017 AMENDED & RESTATED TERM LOAN AGREEMENT WITH CRG SERVICING LLC MANAGED FUNDS.CRG HAS WAIVED ITS RIGHT TO RECEIVE PAYMENT OF CERTAIN CASH COMPENSATION OF UP TO $6 MILLION DOLLARS.IN CONSIDERATION FOR ENTERING AMENDED AGREEMENT, CRG RECEIVED 800,000 COMMON SHARE PURCHASE WARRANTS WITH $2.50 EXERCISE PRICE.  Full Article